MedTrace Logo

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

NCT06418529 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21340

Last updated 2025-07-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn how different types of medicines may improve disease activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes pain and swelling.

The study will look at data from a large, US-based group of RA patients who have taken the below medicines:

* Tofacitinib
* Abatacept
* Tocilizumab or sarilumab

The study will compare clinical disease activity scores of patients on the different medicines taken. The study will also decide whether some patient traits or disease factors play a role in how medicines may improve disease activity.

Conditions

Interventions

DRUG

tofacitinib

New index treatment of tofacitinib

DRUG

tumor necrosis factor inhibitors (TNFi)

New index treatment of TNFi

DRUG

abatacept

New index treatment of abatacept

DRUG

tocilizumab or sarilumab

New index treatment of tocilizumab or sarilumab

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2024-07-19
Completion
2024-07-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06418529 on ClinicalTrials.gov